Disease modifying agents for multiple sclerosis.
Olga Hilas,Priti N Patel,Sum Lam +2 more
TL;DR: Major clinical trials which evaluate the efficacy and safety data of approved disease modifying agents for the treatment of various types of multiple sclerosis are summarized to show interferon beta products continue to be the mainstay of therapy in many patients, however, other treatments are proving to be at least as effective in the management ofVarious types of MS.
read more
Abstract: Objective:
To summarize major clinical trials which evaluate the efficacy and safety data of approved disease modifying agents for the treatment of various types of multiple sclerosis.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Adverse effects of biologics: a network meta‐analysis and Cochrane overview
Jasvinder A. Singh,George A. Wells,Robin Christensen,Elizabeth Tanjong Ghogomu,Lara J Maxwell,John K MacDonald,Graziella Filippini,Nicole Skoetz,Damian K Francis,Luciane Cruz Lopes,Gordon Guyatt,Jochen Schmitt,Loredana La Mantia,Tobias Weberschock,Juliana F. Roos,Hendrik Siebert,Sarah. Hershan,Chris Cameron,Michael P. Lunn,Peter Tugwell,Peter Tugwell,Rachelle Buchbinder +21 more
TL;DR: The rate of serious adverse events, serious infections, lymphoma, and congestive heart failure were not statistically significantly different between biologics and control treatment, and direct comparisons revealed that abatacept and anakinra were associated with a significantly lower risk ofserious adverse events compared to most other biologicics.
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.
Ranjan Dutta,Bruce D. Trapp +1 more
TL;DR: The etiology, mechanisms and progress made in determining the cause of axonal and neuronal loss in MS are discussed, with a focus on the sixth decade of the disease.
443
Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
TL;DR: In the article “Randomized, comparative study of interferon β-1a treatment regimens in MS: the …
109
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group.
Peter Rieckmann,Alexey Boyko,Diego Centonze,Irina Elovaara,Gavin Giovannoni,Eva Havrdova,Otto Hommes,Jurg Kesselring,Gisela Kobelt,Dawn Langdon,Jacques LeLorier,Sarah A. Morrow,Celia Oreja-Guevara,Sven Schippling,Christoph Thalheim,Heidi Thompson,Patrick Vermersch +16 more
TL;DR: The MS in the 21st Century Steering Group devised a set of themes that require action with regard to patient engagement in MS, namely: setting and facilitating engagement by education and confidence-building, increasing the importance placed on QoL and patient concerns through patient-reported outcomes (PROs); and encouraging treatment adherence through engagement.
109
New approaches in the management of multiple sclerosis
TL;DR: Data from clinical trials of newer agents of potential benefit in MS are provided, with reductions in MS relapse rates and improvements in T₂ or gadolinium-enhancing lesion burdens reported from Phase III trials that include fingolimod, alemtuzumab, cladribine, and rituximab.
References
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald,A Compston,Gilles Edan,Donald E. Goodkin,Hans-Peter Hartung,Fred D. Lublin,Henry F. McFarland,Donald W. Paty,Chris H. Polman,Stephen C. Reingold,Magnhild Sandberg-Wollheim,William A. Sibley,Alan J. Thompson,Stanley van den Noort,Brian Y. Weinshenker,Jerry S. Wolinsky +15 more
TL;DR: The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.
7.4K
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Chris H. Polman,Stephen C. Reingold,Gilles Edan,Massimo Filippi,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Luanne M. Metz,Henry F. McFarland,Paul O'Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Brian G. Weinshenker,Jerry S. Wolinsky +13 more
TL;DR: New evidence and consensus now strengthen the role of these criteria in the multiple sclerosis diagnostic workup to demonstrate dissemination of lesions in time, to clarify the use of spinal cord lesions, and to simplify diagnosis of primary progressive disease.
5.2K
Defining the clinical course of multiple sclerosis Results of an international survey
TL;DR: An international survey of clinicians involved with MS revealed areas of consensus about some terms classically used to describe types of the disease and other areas for which there was lack of consensus and proposed standardized definitions for the most common clinical courses of patients with MS.
3.7K
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Chris H. Polman,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,David Miller,J. Theodore Phillips,Fred D. Lublin,Gavin Giovannoni,A Wajgt,Martin Toal,F Lynn,Michael Panzara,Alfred Sandrock +12 more
TL;DR: Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
3.3K
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
Lawrence Jacobs,Diane Cookfair,Richard A. Rudick,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,Carl V. Granger,Jack H. Simon,John J. Alam,David M. Bartoszak,Dennis Bourdette,Jonathan Braiman,Carol M. Brownscheidle,Michael E. Coats,Stanley Cohan,David S. Dougherty,R. P. Kinkel,Michele Mass,Frederick Munschauer,Roger L. Priore,Patrick M. Pullicino,Barbara J. Scherokman,Bianca Weinstock-Guttman,Ruth H. Whitham +25 more
TL;DR: Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
2.5K
Related Papers (5)
H. Wiendl,Ralf Gold,Thomas Berger,Tobias Derfuss,Ralf A. Linker,Mathias Mäurer,Orhan Aktas,Karl Baum,Martin Berghoff,Stefan Bittner,Andrew T. Chan,Adam Czaplinski,Florian Deisenhammer,Franziska Di Pauli,Renaud Du Pasquier,Christian Enzinger,Elisabeth Fertl,Achim Gass,Klaus Gehring,Claudio Gobbi,Norbert Goebels,Michael Guger,Aiden Haghikia,Hans-Peter Hartung,Fedor Heidenreich,Olaf Hoffmann,Boris Kallmann,Christoph Kleinschnitz,Luisa Klotz,Verena I. Leussink,Fritz Leutmezer,Volker Limmroth,Jan D. Lünemann,Andreas Lutterotti,Sven G. Meuth,Uta Meyding-Lamadé,Michael Platten,Peter Rieckmann,Stephan Schmidt,Hayrettin Tumani,Frank Weber,Martin S. Weber,Uwe K. Zettl,Tjalf Ziemssen,Frauke Zipp +44 more